Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
AbbVie logo

AbbVie Cash Flow Statement

Operating, investing, and financing cash movements

AbbVie generated $21.2B in operating cash flow over the trailing twelve months. After $1.2B in capital expenditures, free cash flow was $20.0B. Free cash flow increased 0.3% year-over-year. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$21.2BNet Cash From Investing (TTM)-$6.5BNet Cash From Financing (TTM)-$10.5BCapital Expenditures (TTM)$1.2BDepreciation And Amortization Cf (TTM)$762.0MNet Change In Cash (TTM)$4.2B
Latest FilingQ1 2026
Report Date2026-05-08
Market Cap$397.12B
P/E Ratio109.25
ROE-138.85%

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Non-cash litigation reserve adjustments$167M-$729M-$21M-$319M—$150M
Other non-cash income (expense)—-$17M-$79M$90M$9M$22M
Payment for contingent consideration liability (operating)$539M$549M$859M$776M$681M$722M
Other non-cash income (expense)—-$17M-$79M$90M$9M$22M
Change in accounts payable$1.2B-$696M—$1.7B—-$1.6B
Change in accounts receivable-$387M$1.5B$17M$156M—-$87M
Change in inventories$128M$155M$56M$0$25M$184M
Deferred income taxes-$767M-$28M-$272M—-$385M$137M
Other Non-Cash Income (Expense)—-$17M-$79M$90M$9M$22M
Other Non-cash Income (Expense)—-$17M-$79M$90M$9M$22M
Other Non-cash Income (Expense)—-$17M-$79M$90M$9M$22M
Net cash from operating activities$7B$1.6B$5.2B$7B$5.2B$3.8B
Net income$0$1.3B$941M$188M$1.8B$697M
Other non-cash income (expense)—-$17M-$79M$90M$9M$22M
Amortization of capitalized software and acquired intangible assets$1.9B$1.9B$1.9B$1.9B$1.8B$1.7B
Contingent consideration fair value adjustments$279M$1.5B$2.8B$776M$1.4B$2.4B
Depreciation$206M$181M$186M$192M$203M$188M
Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable-$1.8B$378M-$1.4B-$411M—-$81M
Increase (Decrease) in Prepaid Expense and Other Assets—$628M——$658M$150M
Other Noncash Income (Expense)—-$17M-$79M$90M$9M$22M
Other Non-cash Income and Expense—-$17M-$79M$90M$9M$22M
Other Non-Cash Adjustments—-$17M-$79M$90M$9M$22M
Other Non-Cash Income and Expense—-$17M-$79M$90M$9M$22M
Stock-based compensation$164M$410M$179M$209M$157M$444M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Repayments of other short-term debt—$0$0$2B$791M$2B
Repayments of Other Short-Term Debt—$0$0$2B$791M$2B
Repayments of other short-term debt—$0$0$2B$791M$2B
Proceeds from issuance of debt$2B$4B———$8B
Dividends paid$2.8B$2.9B$2.9B$2.9B$2.9B$3.1B
Other, net$1M$67M—$37M—$2M
Proceeds from (repayments of) short-term borrowings, net$0$1.6B———-$499M
Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security$5.8B$3B$3.8B$9M$8M$0
Repayments of Other Short-Term Debt—$0———$2B
Payment of Deferred Purchase Consideration$0$67M-$35M$37M-$69M$2M
Noncontrolling interest transactions and other$1M$67M—$37M—$2M
Repayments of Other Short-term Debt—$0$0$2B$791M$2B
Net cash from financing activities-$6.9B-$1.3B-$2.7B-$4.6B-$4.2B$919M
Noncontrolling Interests Activity and Other$1M$67M—$37M—$2M
Repayments of Other Short-Term Debt—$0$0$2B$791M$2B
Repurchases of common stock$358M$961M$12M$4M$3M$1.5B
Repayments of Other Short-Term Debt—$0$0$2B$791M$2B
Repayments of other short-term debt—$0$0$2B$791M$2B

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquisitions, net of cash acquired—$204M———$0
Capital expenditures$291M$235M$269M$381M$329M$265M
Payment for (Proceeds from) Other Investing Activity-$197M-$38M-$11M$77M$1M$43M
Payments to Acquire Other Investments$1.8B$334M$940M$2.8B$1.2B$266M
Net cash from investing activities-$1.9B-$735M-$1.2B-$3.3B-$1.5B-$574M

Free Cash Flow

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Free cash flow$6.8B$1.4B$4.9B$6.6B$4.9B$3.6B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$46M$9M$30M—$11M-$12M
Net increase (decrease) in cash-$1.7B-$349M$1.3B-$838M-$400M$4.2B

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interest paid$702.8M$750.5M$750.5M$750.5M$750.5M—